4.5 Review

Stabilization of miRNAs in esophageal cancer contributes to radioresistance and limits efficacy of therapy

期刊

BIOCHIMIE
卷 156, 期 -, 页码 148-157

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biochi.2018.10.006

关键词

microRNAs; Tumor resistance; Radiosenstivity; Radioresistance; Esophageal cancer

资金

  1. Department of Science and Technology of India through the Ramanujan Fellowship [SR/S2/RJN-95/2011, SR/S2/RJN-03/2012]
  2. NIH/NCI [CA093729]
  3. Department of Biotechnology, India [6242-P30/RGCB/PMD/DBT/AKJN/2015]
  4. Indian Council of Medical Research [5/13/81/2013-NCD-III]
  5. Central University of Punjab

向作者/读者索取更多资源

The five-year survival rate of esophageal cancer patients is less than 20%. This may be due to increased resistance (acquired or intrinsic) of tumor cells to chemo/radiotherapies, often caused by aberrant cell cycle, deregulated apoptosis, increases in growth factor signaling pathways, and/or changes in the proteome network. In addition, deregulation in non-coding RNA-mediated signaling pathways may contribute to resistance to therapies. At the molecular level, these resistance factors have now been linked to various microRNA (miRNAs), which have recently been shown to control cell development, differentiation and neoplasia. The increased stability and dysregulated expression of miRNAs have been associated with increased resistance to various therapies in several cancers, including esophageal cancer. Therefore, miRNAs represent the next generation of molecules with tremendous potential as biomarkers and therapeutic targets. However, detailed studies on miRNA-based therapeutic interventions are still in their infancy. Hence, in this review, we have summarized the current status of microRNAs in dictating the resistance/sensitivity of tumor cells to chemotherapy and radiotherapy. In addition, we have discussed various strategies to increase radiosensitivity, including targeted therapy, and the use of miRNAs as radiosensitive/radioresistance biomarkers for esophageal cancer in the clinical setting. (c) 2018 Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据